ArticleAntimicrobial agents and chemotherapy2007
Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection.
Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- Pharmacological Intervention for Refractory Biofilm Infection After Hemipelvic Replacement Surgery: Multidisciplinary Management of a Case of Giant Cell Tumor of Bone.The American journal of case reports · 2025Article
- Organism profiles and empirical treatments for periprosthetic joint infections.Journal of orthopaedic surgery and research · 2025Article
- Comparison ofFrontiers in microbiology · 2023Article
- Controversy about the Role of Rifampin in Biofilm Infections: Is It Justified?Antibiotics (Basel, Switzerland) · 2021Article
- SAAP-148 Eradicates MRSA Persisters Within Mature Biofilm Models Simulating Prosthetic Joint Infection.Frontiers in microbiology · 2021Article
- Antibiotic treatment regimens for bone infection after debridement: a study of 902 cases.BMC musculoskeletal disorders · 2020Article
- Role of Rifampin against Staphylococcal Biofilm InfectionsAntimicrobial agents and chemotherapy · 2019Review
- Orthopedic Prosthetic Infections: Diagnosis and Orthopedic Salvage.Seminars in plastic surgery · 2016Article
- The role of microbial biofilms in prosthetic joint infections.Acta orthopaedica · 2015Review
- High activity of Fosfomycin and Rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model.Antimicrobial agents and chemotherapy · 2014Article
- Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model.Antimicrobial agents and chemotherapy · 2014Article
- Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control study.Infection · 2013Article
- Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections.Antimicrobial agents and chemotherapy · 2012Article
- Role of rifampin against Propionibacterium acnes biofilm in vitro and in an experimental foreign-body infection model.Antimicrobial agents and chemotherapy · 2012Article
- Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model.Antimicrobial agents and chemotherapy · 2011Article
- Unpredictable effects of rifampin as an adjunctive agent in elimination of rifampin-susceptible and -resistant Staphylococcus aureus strains grown in biofilms.Antimicrobial agents and chemotherapy · 2010Article
- Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin.Antimicrobial agents and chemotherapy · 2009Article
- Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.Antimicrobial agents and chemotherapy · 2009Article
- Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection.Antimicrobial agents and chemotherapy · 2008Article
- Diagnosis and treatment of implant-associated septic arthritis and osteomyelitis.Current infectious disease reports · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared the efficacy of a novel rifamycin derivative, ABI-0043, with that of rifampin, alone and in combination with levofloxacin, against methicillin-susceptible Staphylococcus aureus ATCC 29213 in a guinea pig tissue-cage infection model. The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively. After a single intraperitoneal dose of 12.5 mg/kg of body weight, the peak concentration in cage fluid was 1.13 micarog/ml of ABI-0043 and 0.98 microg/ml of rifampin. Five days after completion of treatment, levofloxacin administered alone (5 mg/kg/12 h) resulted in bacterial counts in cage fluid that were similar to those for untreated controls (>8.0 log(10) CFU/ml), whereas rifampin and ABI-0043 administered alone (12.5 mg/kg/12 h) decreased the mean titers of bacteria +/- standard deviations to 1.43 +/- 0.28 log(10) and 1.57 +/- 0.53 log(10) CFU/ml, respectively, in cage fluid. In combination with levofloxacin, both rifamycins cleared bacteria from the cage fluid. The cure rates of cage-associated infections with rifampin and ABI-0043 administered alone were 46% and 58%, respectively, and increased to 88% and 92% in combination with levofloxacin. Emergence of rifamycin resistance was observed in 42% of cages after ABI-0043 therapy and in 38% of cages after rifampin therapy; no emergence of resistance occurred with combination treatment with levofloxacin. In conclusion, ABI-0043 had cure rates comparable to that of rifampin. ABI-0043 in combination with a quinolone has the potential for treatment of implant-associated infections caused by susceptible strains of S. aureus, potentially without drug-drug interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.